Phase 2 LITESPARK-003 Results Suggest Continued Study of Novel First-Line Combo for Advanced Kidney Cancer
Current first-line treatment for advanced clear-cell renal cell carcinoma includes anti-PD1 or anti-PD-L1 immunotherapy in combination with a CTLA-4 inhibitor or a VEGF tyrosine kinase inhibitor such as cabozantanib. These options have improved...
17-Jan-2025 9:00 AM EST
Add to Favorites